Results 11 to 20 of about 4,485 (161)

Critical appraisal of the safety and efficacy of insulin detemir in glycemic control and cardiovascular risk management in diabetics

Diabetes, Metabolic Syndrome and Obesity, 2010
Jean-Pierre Le FlochDepartment of Diabetology, Medical Clinic, Villecresnes, FranceAbstract: Insulin detemir is an analog of human insulin designed to provide a long duration of basal insulin action.
Jean-Pierre Le Floch
doaj   +4 more sources

Insulin detemir in the treatment of type 1 and type 2 diabetes [PDF]

Vascular Health and Risk Management, 2006
Jean-Christophe Philips, André ScheenDivision of Diabetes, Nutrition & Metabolic Disorders, Department of Medicine, CHU Sart-Tilman, University of Liège, Liège, Belgium Abstract: Insulin detemir is a soluble long-acting human ...
Jean-Christophe Philips, André Scheen   +1 more
doaj   +2 more sources

Detemir as a once-daily basal insulin in type 2 diabetes

Clinical Pharmacology: Advances and Applications, 2011
Scott E NelsonCleveland Family Medicine, Cleveland, Mississippi, USABackground: Insulin detemir, a long-acting basal insulin analog, is labeled for once-daily or twice-daily dosing in patients with type 1 (T1DM) or type 2 (T2DM) diabetes mellitus ...
Nelson SE
doaj   +1 more source

Tolerability, safety and adherence to treatment with insulin detemir injection in the treatment of type 2 diabetes

Patient Preference and Adherence, 2008
Athena Philis-TsimikasScripps Whittier Diabetes Institute, La Jolla, CA, USAAbstract: The progressive nature of type 2 diabetes poses challenges in the clinic: treatment must be continually reviewed and adjusted in response to the patient’s ...
Athena Philis-Tsimikas
doaj   +1 more source

Cerebrocortical beta activity in overweight humans responds to insulin detemir.

PLoS ONE, 2007
BackgroundInsulin stimulates cerebrocortical beta and theta activity in lean humans. This effect is reduced in obese individuals indicating cerebrocortical insulin resistance.
Otto Tschritter, Anita M Hennige, Hubert Preissl, Katarina Porubska, Silke A Schäfer, Werner Lutzenberger, Fausto Machicao, Niels Birbaumer, Andreas Fritsche, Hans-Ulrich Häring   +9 more
doaj   +3 more sources

Insulin detemir for the treatment of obese patients with type 2 diabetes

Diabetes, Metabolic Syndrome and Obesity, 2012
Priscilla A Hollander1,21Baylor Endocrine Center, 2Baylor Medical Center, Dallas, Texas, USAAbstract: The risk for developing type 2 diabetes (T2DM) is greater among obese individuals. Following onset of the disease, patients with T2DM become more likely
Hollander PA
doaj   +1 more source

Two-way crossover comparison of insulin glargine and insulin detemir in basal-bolus therapy using continuous glucose monitoring

Diabetes, Metabolic Syndrome and Obesity, 2011
Shinya Abe1,2, Gaku Inoue1,2, Satoru Yamada1,3, Junichiro Irie1,3, Hiroyuki Nojima2, Kaoru Tsuyusaki2, Kensuke Usui2, Koichiro Atsuda2, Toshikazu Yamanouchi41Diabetes Center, Kitasato Institute Hospital, 2Center for Clinical Pharmacy and Clinical ...
Abe S, Inoue G, Yamada S, Irie J, Nojima H, Tsuyusaki K, Usui K, Atsuda K, Yamanouchi T   +8 more
doaj   +1 more source

The role of insulin detemir in overweight type 2 diabetes management

Vascular Health and Risk Management, 2009
Yared N Demssie1, Naveed Younis2, Handrean Soran31Department of Diabetes and Endocrinology, Salford Royal Foundation NHS Trust, Salford, UK; 2Department of Medicine, University Hospital South Manchester Foundation NHS Trust, Wythenshawe, Manchester, UK ...
Yared N Demssie, Naveed Younis, Handrean Soran   +2 more
doaj   +1 more source

Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes - A randomized clinical trial [PDF]

, 2004
OBJECTIVE—Insulin detemir is a soluble long-acting basal insulin analog designed to overcome the limitations of conventional basal insulin formulations.
Bartley, Paul, Russell-Jones, David, Lang, Hanne, Landin-Olsson, M., Lang, H., Hanaire-Broutin, Helene, Draeger, Eberhard, Hanaire-Broutin, H., Abrams, Pascale, Landin-Olsson, Mona,, Russell-Jones, D., Bartley, Paul Anthony, Draeger, E., Hylleberg, Birgitte, Bartley, P., Hylleberg, B., Heeg, J.E., Home, Philip, Lund University., Home, P., Heeg, Jan-Evert, Landin-Olsson, Mona   +21 more
core   +1 more source

Insulin analogues dosing and costs - comparing real-life daily doses of insulin detemir and insulin glargine in type 2 diabetes patients

BMC Endocrine Disorders, 2012
Background The uncertainties regarding dose similarities between basal long-acting insulin analogues remain. Recent real-world studies indicate dose similarities between insulin detemir and insulin glargine, but further studies are still warranted.
Jakobsen Marie, Dalsgaard Mette, Hørmann Morten, Møller Daniél   +3 more
doaj   +1 more source